indigo
Botanicalexperimental
Indigo carmine, or 5,5′-indigodisulfonic acid sodium salt, is an organic salt derived from indigo by aromatic sulfonation, which renders the compound soluble in water. Like indigo, it produces a blue color, and is used in food and other consumables, cosmetics, and as a medical contrast agent and staining agent; it also acts as a pH indicator. It is approved for human consumption in the United States and European Union. It has the E number E132, and is named Blue No. 2 by the US Federal Food, Drug, and Cosmetic Act. — Wikipedia
Clinical trial activity
12 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
6
Phase 4
1
Earliest trial started Sep 1, 2009 (NCT00999687)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C1/C(=C2\Nc3ccccc3C2=O)Nc2ccccc21- Mol. weight
- 262.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIndigo carmine ↗
- ChEMBLCHEMBL599552 ↗
- WikipediaIndirubin ↗
- WikipediaIndigo ↗
Also known as
- baptista
- indigo
- indigo
- indigo
- indigo naturalis
- indigo naturalis extract
- realgar-indigo naturalis
- rif
- wild indigo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04228445 | Phase 3 | Feb 1, 2020 | Provepharm Sas |
| NCT04175587 | Phase 3 | Dec 1, 2019 | Government of China, Peking University |
| NCT02899169 | Phase 3 | Sep 1, 2016 | Jiao Tong University, People's Liberation Army of China |
| NCT02669888 | Phase 2 | Oct 1, 2015 | Chang Gung University, Government of Taiwan |
| NCT02411435 | Phase 1 | Jul 1, 2015 | GlaxoSmithKline, ViiV Healthcare |
| NCT01901705 | Phase 2 | Feb 1, 2013 | China Medical University |
| NCT02088281 | Phase 2 | Nov 1, 2012 | Chang Gung University, Government of Taiwan |
| NCT01755325 | Phase 3 | Nov 1, 2012 | Jiao Tong University, Shanghai Ruijin Hospital North |
| NCT02200978 | Phase 4 | Sep 1, 2011 | South China Children's Leukemia Group, Sun Yat-Sen University |
| NCT01445886 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2011 | Chang Gung University |
| NCT01022502 | Phase 2 | Nov 1, 2009 | Chang Gung University |
| NCT00999687 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2009 | Chang Gung University |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chang Gung University | Academic/Hospital | 5 | 5 | 2 | 2009 |
| Government of Taiwan | Government | 2 | 0 | 1 | 2012 |
| Jiao Tong University | Academic/Hospital | 2 | 1 | 1 | 2012 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2015 |
| Government of China | Government | 1 | 0 | 1 | 2019 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2016 |
| Provepharm Sas | For profit | 1 | 1 | 1 | 2020 |
| Shanghai Ruijin Hospital North | Academic/Hospital | 1 | 1 | 1 | 2012 |
| South China Children's Leukemia Group | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| ViiV Healthcare | For profit | 1 | 1 | 1 | 2015 |
13 organizations
Page 1 / 1